Hetero Labs Ltd. has identified angiopoietin-1 receptor (TEK; hTIE2), EGFR (HER1; erbB1), hepatocyte growth factor receptor (HGFR; MET), proto-oncogene tyrosine-protein kinase receptor ret (RET; CDHF12; PTC), tyrosine-protein kinase receptor UFO (AXL) and vascular endothelial growth factor receptor 2 (VEGFR2; FLK1) inhibitors reported to be useful for the treatment of cancer.